WCLC 2025 - Posters & ePosters-P3.12.58 Initial Results From Phase 1/2 Study of the RET-Selective Inhibitor Vepafestinib in Patients With RET-Aberrant Solid Tumors

P3.12.58 Initial Results From Phase 1/2 Study of the RET-Selective Inhibitor Vepafestinib in Patients With RET-Aberrant Solid Tumors

Asset Subtitle

Kiyotaka Yoh

Meta Tag

Speaker Kiyotaka Yoh

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy